Every 8-K that Neuraxis, Inc. (NRXS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NRXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRXS filings page.
Neuraxis, Inc. (NRXS) reports that a previously approved Stock Option Exchange became effective on July 24, 2026. Stockholders had approved cancelling 1,319,394 outstanding stock options under a prior plan and issuing an equivalent number of restricted stock units (RSUs) under the 2022 Omnibus Securities and Incentive Plan on a one-for-one basis. As a result, CEO Brian Carrico, CMO Adrian Miranda, and Chief Regulatory Officer Thomas Carrico received 199,188, 199,106, and 193,678 RSUs, all vesting immediately.
On August 13, 2026, after Compensation Committee approval, Neuraxis granted additional RSUs under the 2022 Plan: 193,329 to Brian Carrico, 141,479 to CFO Timothy Henrichs, 133,341 to Adrian Miranda, and 135,906 to Thomas Carrico, vesting in three equal annual installments over three years. The Compensation Committee also approved one-time equity awards totaling 127,120 shares of common stock to independent directors in recognition of prior Board service, following a review by an independent compensation consultant that found historical director compensation below market levels.
Neuraxis, Inc. reported that its Board of Directors authorized and the company declared a stock dividend on its Series B Preferred Stock for the second quarter of 2026. This dividend will be paid in shares of Neuraxis common stock.
The number of common shares each Series B holder receives will equal that holder’s accrued and unpaid dividends from April 1, 2026 through the record date, divided by $2.38. A total of approximately 80,463 shares of common stock are expected to be issued. The dividend is payable on July 29, 2026 to Series B holders of record as of the close of business on July 21, 2026. No fractional shares will be issued; instead, any fractional entitlement will be settled in cash using the same $2.38 figure.
Neuraxis, Inc. held its annual stockholder meeting, with 10,206,763 votes represented, equivalent to approximately 73.51% of outstanding voting power, establishing a quorum. Six directors were elected, each receiving at least 96.64% of votes cast for their seats.
Stockholders ratified the appointment of Rosenberg Rich Baker Berman, P.A. as independent auditor for the year ending December 31, 2026, with 10,187,191 votes in favor. They also approved an amendment to the 2022 Omnibus Securities and Incentive Plan, which again revised Section 5.1, and approved the Neuraxis, Inc. 2025 Employee Stock Purchase Plan.
Before the meeting, the board amended Section 5(c) of the Employee Stock Purchase Plan so that no employee may receive purchase rights if, immediately after grant, the employee would own 10% or more of the company’s voting power or value, replacing the original 5% limitation.
Neuraxis, Inc. increased the capacity of its existing at-the-market stock offering program. The company may now sell shares of its common stock for an aggregate offering price of up to $11,500,000 through Craig-Hallum Capital Group LLC under a previously effective Form S-3 shelf registration.
The agreement was originally sized at up to $6,270,000. From August 29, 2025 through April 20, 2026, Neuraxis sold 1,125,281 shares of common stock under this arrangement. A new prospectus supplement and a related legal opinion from Lucosky Brookman LLP support the expanded program.
Neuraxis, Inc. released preliminary, unaudited figures for the quarter ended March 31, 2026. The Company expects cash and cash equivalents of about $7.1 million as of that date, providing a snapshot of its available liquidity.
For the same three-month period, Neuraxis anticipates net sales of approximately $1.6 million, up from about $0.9 million a year earlier, showing strong year-over-year revenue growth. On a preliminary basis, it expects gross profit of about $1.4 million and an operating loss of about $1.7 million, indicating the business is still not profitable.
The Company emphasizes these numbers are preliminary and unaudited and may change as the quarter-end close is completed and the independent registered public accounting firm reviews the full financial statements.
NeurAxis (NRXS) reported two updates. First, the company received FDA 510(k) clearance for its percutaneous electrical nerve field stimulation (PENFS) technology to treat functional abdominal pain associated with functional dyspepsia, and FD-related nausea symptoms, in patients aged 8 years and older. The FDA reviewed randomized trials and real‑world evidence in pediatric and young adult populations and extrapolated to adults, marking the first clearance or approval specifically addressing FD in the adult population.
Second, NeurAxis updated its at‑the‑market program. The company previously established an ATM of up to $3,300,000 and disclosed that from August 29, 2025 through October 23, 2025 it sold no shares. On October 23, 2025, it filed a prospectus supplement to increase the ATM capacity to $6,270,000, providing flexibility to raise equity over time through Craig‑Hallum Capital Group as sales agent.
Neuraxis, Inc. disclosed preliminary, unaudited results for the quarter and nine months ended September 30, 2025. The company expects cash and cash equivalents of approximately $4.4 million as of September 30, 2025.
For the three months ended September 30, 2025, Neuraxis estimates net sales of about $0.8 million, gross profits of about $0.7 million, and an operating loss of about $2.1 million. For the nine months ended September 30, 2025, net sales are expected to be about $2.6 million, compared with about $1.9 million for the same period in 2024.
Management emphasized these figures are preliminary and subject to change as the quarter-end close is completed. The company’s independent registered public accounting firm has not audited or reviewed these estimates, and final financial statements will be completed subsequent to this report. The company cautioned that adjustments could be material and advised against undue reliance on these preliminary figures.
Neuraxis, Inc. has entered into an At-The-Market (ATM) Offering Agreement with Craig-Hallum Capital Group LLC that allows the company to offer and sell shares of its common stock, at the company's discretion, through the sales agent. The agreement permits aggregate sales with an offering price up to $3,300,000. The arrangement gives Neuraxis a standing mechanism to raise capital by selling shares into the market over time rather than through a single underwritten offering.
This filing discloses the existence and terms of the sales-agent relationship and the maximum aggregate offering amount; no specific sales, pricing, or use-of-proceeds details are included in the provided text.